DOI: https://doi.org/10.24061/1727-4338.XIV.4.54.2015.48

ПРИГНІЧЕННЯ СИГНАЛЬНОГО ШЛЯХУ ЯДЕРНОГО ФАКТОРА – КВ (NF-KB) ЯК ПОТЕНЦІЙНА СТРАТЕГІЯ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРІТУ

A. T. Dolzhenko, S. Sagalovsky

Анотація


Ядерний фактор – кВ (NF-kB) є одним з головних транскрипційних факторів, які приймають участь у розвитку запальних реакцій і видіграючих основну роль у пошкодженні сіновіальної тканини і патогенезу різних ревматоїдних захворювань, у тому числі, ревматоїдного артриту. NF-kB видіграє важну роль не тільки у розвитку запалення, але і у порушенні хрящевої тканини, клітинної діференціації, проліферації, ангіогенезу і подавлення апоптозу. У результаті встановлення важної ролі NF-kB сигнального шляху у деградації суглобового хрящу і прогресуванні ревматоїдного артріту, дозволило переглянути механізми дії звісних протиревматичних середовищ, таких як кортикостероїди, нестероїдні протизапальні препарати. Розуміння значності ролі NF-kB сигнального каскаду у патогенезі ревматоїдного артріту сприяло запропануванню ідеї пошуку середовищ, інгібіруючих/модулірующих активність молекул сигнального шляху, розробку і впровадження у практику нових  препаратів для лікування захворювання.

Ключові слова


NF-kB сигнальний шлях; фактории транскрипції; запалення; ревматоїдний артріт

Повний текст:

PDF (English)

Посилання


Adli M, Merkhofer E, Cogswell P, Baldwin AS. IKKα and IKKβ each function to regulate NF-kB activation in the THF-induced/canonical pathway. PLoS ONE. 2010;5(2):9428.

Ahn K, Sethi G, Chao TH, et al. Salinosporamide A (NPI-0052) potentiates apoptosis, suppresses osteoclastogenesis, and inhibits invasion through down-modulation of NF-kB-regulated gene products. Blood. 2007;110(7):2286-95.

Anchoori RK, Harikumar KB, Batchu VR, et al. Inhibition of IkB kinase and NF-kB by a novel synthetic compound SK 2009. Bioorg. Med. Chem. 2010;18(1):229-39.

Andreakos E, Smith C, Kiriakidis S, et al. Heterogeneous requirement of IkB kinase 2 for inflammatory cytokine and matrix metalloproteinase production in rheumatoid arthritis. Arthritis Rheumatism. 2003;48(7):1901-12.

Asano S, Fukuda Y, Beck F, et al. Proteasomes: a molecular census of 26 S proteasomes in intact neurons. Science. 2015;347(5):439-42.

Bhatt D, Ghosh S. Regulation of the NF-kB-mediated transcription of inflammatory genes. Front Immunol. 2014;5(1):71-9.

Campo GM, Avenso A, Campo S, et al. Chondroitin-4-sulfate inhibits NF-kB translocation and caspase activation in collagen-induced arthritis in mice. Osteoarthritis Cartilage. 2008;16(12):1474-83.

Chen D, Frezza M, Schmitt S, et al. Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspective. Curr. Cancer Drug Targets. 2011;11(3):239-53.

Choy E. Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis. Rheumatol. 2012;51(5):3-11.

Domagala F, Martin G, Bogdanowicz P, et al. Inhibition of interleulin-1ß-induced activation of MEK/ERK pathway and DNA binding of Nf-kappa B and AP-1: potential mechanism for Diacerein effects in osteoarthritis. Biorheology. 2006;43(3-4):577-87.

Fishman P, Bar-Yehuda S. Rheumatoid arthritis: history, molecular mechanisms and therapeutic application. In: Adenosine receptors from cell biology to pharmacology and therapeutic. Borea PA., ed. Springer Sci.: N.Y; 2010. р. 291-98.

Ganesan N, Pallinti V, Rajasekhar G. Signal transduction pathway in rheumatoid arthritis. SRJM. 2010;3(1):18-21.

Gibofsky A. Overview of epidemiology, pathophysiology, and diagnosis of rheumatoid arthritis. Am. J. Manag. Care. 2012;18(13):295-302.

Gilmore TD, Herscovitch M. Inhibition of NF-kB signaling: 785 and counting. Oncogene. 2006;25(51):6887-99.

Giopanou I, Bravou V, Papanastasopoulos P, et al. Metadherin, p50, and p65 expression in epithelial ovarion neoplasms: an immunohistochemical study. BioMed Res. Int. 2014;2014. ID 178410.

Gupta SC, Sundaram C, Renter S, et al. Inhibiting NF-kB activation by small molecules as a therapeutic strategy. Biochem. Biophys. Acta. 2010;1799(10-12):775-87.

Hayden MS, Ghosh S. NF-kB in immunobiology. Cell Res. 2011; 21(2):223-44.

Herkenham M, Rathore P, Brown P, Listwak SJ. Cautionary notes on the use of NF-kB p65 and p50 antibodes for CNS studies. J. Neuroinflam. 2011;8(2):141-55.

Hoesel B, Schmid JA. The complexity of NF-kB signaling in inflammatory and cancer. Mol.Cancer. 2013;12(1):86-94.

Israel A. The IKK complex, a control regulator of NF-kB activation. Cold Spring Harb Perspect Biol. 2010;2(4):58.

Karin M. Mitogen activated protein kinases as target for development of nivel anti-inflammatory drugs. Ann. Rheum. Dis. 2004;63(1):62-4.

Karin M. Role for IKK2 in muscle: waste not, want not. J. Clin. Invest. 2006;116(11):2866-68.

Kroonen J, Artesi M, Capraro V, et al. Casein kinase II inhibition modulates the DNA damage response but fails to radiosensitize malignant glioma cells. Int. J. Oncol. 2012;41(2):776-82.

Lee SH, Wong LY, Brulois K, et al. Novel phosphorylation of IKKγ/NEMO. Clin. Microbiol. Portal. 2012;3(6):411-12.

Leung CH, Grill SP, Lam W, et al. Novel mechanism of inhibition of nuclear factor-kB DNA-binding activity by diterpenoids isolated from isodan rubescens. Mol. Pharmacol. 2005;68(2):286-97.

Liu L, Hua Y, Wang D, et al. A sesquiterpene lactone from a medical herb inhibits proinflammatory activity of TNF-α by inhibiting ubiquitin-conjugation enzyme UbcH5. Chem.Biol. 2014;21(10):1341-50.

Lowe JM, Menendez D, Bushel P, et al. P53 and NF-kB coregulate proinflammatory gene responses in human macrophages. Cancer Res. 2014;74(8):2182-92.

Mann DA. The NF-kB luciferase mouse: a new toolfor real time measurement of NF-kB activation in the whole animal. Gut. 2002;51(6):769-70.

Oeckinghaus A, Chosh S. The NF-kB family of transcription factors and its regulation. Cold Spring Harb Perspect Biol. 2009;1(4):34.

Reginster JY, Neuprez A, Leeart MP, et al. Role of glucosamine in the treatment for osteoarthritis. Int. 2012;32(10):2959-67.

Royuela M, Rodriguez-Berriguete G, Frail B, Paniagua R. TNF-alpha /IL-1/NF-kB-transduction pathway in human cancer prostate. Nistol. Histopathol. 2008; 23(10):1279-90.

Saadane A, Masters S, DiDonato J, et al. Parthenolide inhibits I kappa B kinase, NF-kappa B activation, and inflammatory response in cystic fibrosis cells and mice. Am. J. Respir. Cell Mol. Biol. 2007;36(6):728-36.

Solt LA, Madge LA, May MJ. NEMO-binding domains of both IKKα and IKKß regulate I kappa B kinase complex assembly and classical NF-kappaB activation. J. Biol. Chem. 2009;284:40:27596-608.

Solt LA, May MJ. The I kappa B kinase complex: master regulator of NF-kB signaling. Immunol. Res. 2008;42(1-3):3-18.

Sun SC. Non-cannonical NF-kB signaling pathway. Cell Res. 2011;21(1):71-85.

Tandon VR, Mahajan A, Singh JB. Gene therapy in rheumatoid arthritis: a novel therapeutic approach. J. Indian Rheumatol. 2005;13(1):98-102.

Tang JR, Micharlis KA, Nozik-Grayck E, et al. The NF-kB inhibitory proteins IkBα and IkBß mediate disparate responces to inflammation in fetal pulmonary endothelial cells. J. Immunol. 2013;190(6):2913-23.

Tas SW, Vervoordeldonk MJBM, Tak PP, et al. Gene therapy targeting nuclear factor –kappa B: towards clinical application in inflammatory diseases and cancer. Curr. Gene Ther. 2009;9(3):160-170.

Tergaonkar V, Li Q, Verma IM. Inhibitors of NF-kB activity. In. NF-kB 7Rel transcription factor family. Liou HC. Ed. Springer Sci., N.Y.; 2006. р.162-178.

Thangjam GS, Dimitropoulou C, Joshi AD, et al. Novel mechanism of attenuation of LPS-indused NF-kB activation by the heat shock protein 90 inhibitor, 17-N- allylamino-17-demethoxygeldanamycin, in human lung microvascular endothelial cells. Am. J. Respir. Cell Mol Biol. 2014;50(5):942-52.

Tomita T, Kunugiza Y, Nomura K, et al. Application of NF-kappa B inhibitor for arthritis. Nichon Rinsho Meneki Gakkai Kaishi. 2009;32(2):71-6.

Trask JO. Nuclear factor kappa B (NF-kB) translocation assay development and validation for high content screening. In: Assay Guidance Manual. Sittampalam S., ed. Eli Lilly. Co, N.Y.; 2012. р.1-22.

Verma IM. Nuclear factor (NF)-kB proteins:therapeutic targets. Ann. Rheum. Dis. 2004;63(2):57-61.

Wang H, Zhang S, Zhong J, et al. The proteasome inhibitor lactacystin exerts ist therapeutic effects on glioma via apoptosis: an in vitro and in vivo study. Int. Med. Res. 2013;13(1):1-10.

Weber A, Wasiliew P, Kracht M. Interleukin-1 (IL-1) pathway. Science Signal. 2010;3(105):1-6.

Xu X, Steere RR, Fedorchuk CA, et al. Activation of epidermal growth factor receptor is required for NTHi-induced NF-kB dependent inflammation. PLoS ONE. 2011;6(11):28216.

Yoon JW, Kang IK, Lee KR, et al. ß-Carboline alkaloid suppresse NF-kB transcriptional activity through inhibition of IKK signaling pathway. J. Toxicol. Environ. Health A. 2005;68(23-24):2005-17.

Yu M, Yeh J, Van Waes C. Protein kinase casein kinase 2 mediates inhibitor-kappaB kinase and aberrant nuclear factor-kappa B activation by serum factor(s) in head and neck squamous carcinoma cells. Cancer Res. 2006;66(13):6722-31.

Zamanian-Daryoush M, Mogensen TH, DiDonato JA, Williams BRG. NF-kB activation by double-stranded-DNA-activated protein kinase (PKR) in mediated through NF-kB-inducing kinase and IkB kinase. Mol. Cell. Biol. 2010;20(4):1278-90.

Zhang JM, An J. Cytokines, inflammation and pain. Int. Anesthesiol. Clin. 2007;45(2):27-37.


Пристатейна бібліографія ГОСТ


1. Adli M. IKKα and IKKβ each function to regulate NF-kB activation in the THF-induced/canonical pathway / M.Adli, E.Merkhofer, P. Cogswell, AS Baldwin // PLoS ONE. – 2010. – Vol.5, N2. –P. a9428.


2. Ahn K, Salinosporamide A (NPI-0052) potentiates apoptosis, suppresses osteoclastogenesis, and inhibits invasion through down-modulation of NF-kB-regulated gene products / K.Ahn, G. Sethi, TH. Chao [et al.] // Blood. – 2007. – Vol.110,N7. – P.2286-2295.


3. Anchoori RK. Inhibition of IkB kinase and NF-kB by a novel synthetic compound SK 2009 / RK. Anchoori, KB. Harikumar, VR.Batchu [et al.] //Bioorg. Med. Chem. – 2010. – Vol.18,N1. – P. 229-239.


4. Andreakos E. Heterogeneous requirement of IkB kinase 2 for inflammatory cytokine and matrix metalloproteinase production in rheumatoid arthritis / E.Andreakos, C.Smith, S. Kiriakidis {et al.] // Arthritis Rheumatism. – 2003. – Vol.48,N7. – 1901-1912.


5. Asano S. Proteasomes: a molecular census of 26 S proteasomes in intact neurons / S.Asano, Y. Fukuda, F.Beck [et al.] // Science. – 2015. – Vol.347,N5. –P.439-442.


6. Bhatt D. Regulation of the NF-kB-mediated transcription of inflammatory genes /D.Bhatt, S.Ghosh // Front Immunol. – 2014. – Vol.5,N1. – P.71-79.


7. Campo GM. Chondroitin-4-sulfate inhibits NF-kB translocation and caspase activation in collagen-induced arthritis in mice / GM.Campo, A.Avenso, S.Campo [et al.] // Osteoarthritis Cartilage. – 2008. –Vol.16,N12. – P. 1474-1483.


8. Chen D. Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspective / D.Chen, M. Frezza, S. Schmitt [et al.] // Curr. Cancer Drug Targets. – 2011. – Vol.11,N3. P.239-253.


9. Choy E. Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis / E.Choy// Rheumatol. – 2012 – Vol.51,N5. –P.3-11.


10. Domagala F. Inhibition of interleulin-1ß-induced activation of MEK/ERK pathway and DNA binding of Nf-kappa B and AP-1: potential mechanism for Diacerein effects in osteoarthritis / F. Domagala, G.Martin; P. Bogdanowicz [et al.] // Biorheology. – 2006. – Vol.43, N3-4 - P.577-587.


11. Fishman P. Rheumatoid arthritis: history, molecular mechanisms and therapeutic application / P.Fishman, S.Bar-Yehuda // In: Adenosine receptors from cell biology to pharmacology and therapeutic. Borea PA., ed. Springer Sci., N.Y. – 2010. – P.291-298.


12. Ganesan N. Signal transduction pathway in rheumatoid arthritis / N.Ganesan, V. Pallinti, G. Rajasekhar// SRJM – 2010 – Vol.3,N1. –P.18-21.


13. Gibofsky A. Overview of epidemiology, pathophysiology, and diagnosis of rheumatoid arthritis /A.Gibovsky // Am. J. Manag. Care – 2012. – Vol.18, N13. – P.295-302.


14. Gilmore TD. Inhibition of NF-kB signaling: 785 and counting / TD. Gilmore, M.Herscovitch // Oncogene. – 2006. – Vol.25,N51. – P.6887-6899.


15. Giopanou I. Metadherin, p50, and p65 expression in epithelial ovarion neoplasms: an immunohistochemical study / I. Giopanou, V. Bravou, P. Papanastasopoulos [et al.] // BioMed Res. Int. – 2014. – Vol.2014. – P. ID 178410.


16. Gupta SC. Inhibiting NF-kB activation by small molecules as a therapeutic strategy / SC.Gupta, C. Sundaram, S.Renter [et al.] // Biochem. Biophys. Acta. – 2010. – Vol.1799,N10-12. – P.775-787.


17. Hayden MS. NF-kB in immunobiology /MS.Hayden, S. Ghosh // Cell Res. – 2011. – Vol.21,N2. – P.223-244.


18. Herkenham M. Cautionary notes on the use of NF-kB p65 and p50 antibodes for CNS studies /M. Herkenham, P.Rathore, P.Brown, SJ.Listwak // J. Neuroinflam. – 2011. – Vol.8,N2. – P.141-155.


19.Hoesel B. The complexity of NF-kB signaling in inflammatory and cancer / B. Hoesel, JA Schmid // Mol.Cancer. – 2013. – Vol.12,N1. – P.86-94.


20 Israel A. The IKK complex, a control regulator of NF-kB activation / A.Israel // Cold Spring Harb Perspect Biol. – 2010. – Vol.2, N4. –P. a158.


21. Karin M. Mitogen activated protein kinases as target for development of nivel anti-inflammatory drugs / M.Karin // Ann. Rheum. Dis. -2004. –Vol.63,N1. –P. 62-64.


22. Karin M. Role for IKK2 in muscle: waste not, want not / M. Karin // J. Clin. Invest. – 2006. –Vol.116,N11. – P. 2866-2868.


23. Kroonen J. Casein kinase II inhibition modulates the DNA damage response but fails to radiosensitize malignant glioma cells / J.Kroonen, M.Artesi, V.Capraro [et al.] // Int. J. Oncol. – 2012. – Vol.41,N2. – P. 776-782.


24. Lee SH. Novel phosphorylation of IKKγ/NEMO/ SH. Lee, LY. Wong, K. Brulois [et al.] // Clin. Microbiol. Portal. – 2012. – Vol.3,N6. – P.e411-412.


25. Leung CH. Novel mechanism of inhibition of nuclear factor-kB DNA-binding activity by diterpenoids isolated from isodan rubescens / CH.Leung, SP.Grill, W.Lam [et al.] // Mol.Pharmacol. – 2005. – Vol.68,N2. – P.286-297.


26. Liu L. A sesquiterpene lactone from a medical herb inhibits proinflammatory activity of TNF-α by inhibiting ubiquitin-conjugation enzyme UbcH5 / L. Liu, Y.Hua., D.Wang [et al.]// Chem.Biol. – 2014. – Vol.21,N10. – P.1341-1350.


27. Lowe JM. P53 and NF-kB coregulate proinflammatory gene responses in human macrophages /JM.Lowe, D. Menendez, P. Bushel [et al.] // Cancer Res. – 2014. – Vol.74,N8. – P. 2182-2192.


28. Mann DA. The NF-kB luciferase mouse: a new toolfor real time measurement of NF-kB activation in the whole animal /DA Mann // Gut. – 2002. – Vol.51,N6. –P.769-770.


29. Oeckinghaus A. The NF-kB family of transcription factors and its regulation / A.Oeckinghaus, S. Chosh // Cold Spring Harb Perspect Biol. – 2009. – Vol.1,N4 – P. a34.

 

30. Reginster JY. Role of glucosamine in the treatment for osteoarthritis / JY. Reginster, A. Neuprez, MP. Leeart [et al.] // Rheumatol. Int. – 2012. – Vol.32, N10. –P.2959-2967.


31. Royuela M. TNF-alpha /IL-1/NF-kB-transduction pathway in human cancer prostate / M. Royuela, G.Rodriguez-Berriguete, B.Frail, R.Paniagua // Nistol. Histopathol. – 2008. – Vol.23,N10. – P. 1279-1290.


32. Saadane A. Parthenolide inhibits I kappa B kinase, NF-kappa B activation, and inflammatory response in cystic fibrosis cells and mice / A. Saadane, S.Masters, J.DiDonato [et al.] // Am. J. Respir. Cell Mol. Biol. – 2007. – Vol.36,N6. – P. 728-736.


33. Solt LA. NEMO-binding domains of both IKKα and IKKß regulate I kappa B kinase complex assembly and classical NF-kappaB activation / LA Solt, LA Madge, MJ May // J. Biol. Chem. – 2009. –Vol.284,N40. –P.27596-27608.


34. Solt LA. The I kappa B kinase complex: master regulator of NF-kB signaling / LA Solt, MJ May// Immunol. Res. – 2008. – Vol.42,N1-3. –P.3-18.


35. Sun SC. Non-cannonical NF-kB signaling pathway / SC. Sun // Cell Res. – 2011. – Vol.21,N1. – P. 71-85.


36. Tandon VR. Gene therapy in rheumatoid arthritis: a novel therapeutic approach / VR. Tandon, A. Mahajan, JB. Singh // J.Indian Rheumatol. – 2005. – Vol.13,N1. – P.98-102.


37. Tang JR. The NF-kB inhibitory proteins IkBα and IkBß mediate disparate responces to inflammation in fetal pulmonary endothelial cells /JR. Tang, KA.Micharlis, E. Nozik-Grayck [et al.] // J.Immunol. – 2013. -Vol.190,N6. – P. 2913-2923.


38. Tas SW. Gene therapy targeting nuclear factor –kappa B: towards clinical application in inflammatory diseases and cancer / SW.Tas, MJBM. Vervoordeldonk, PP. Tak [et al.] // Curr. Gene Ther. – 2009. – Vol.9,N3. – P.160-170.


39. Tergaonkar V. Inhibitors of NF-kB activity / V. Tergaonkar, Q.Li, IM. Verma// In. NF-kB 7Rel transcription factor family. Liou HC. Ed. Springer Sci., N.Y., 2006. – P.162-178.


40. Thangjam GS. Novel mechanism of attenuation of LPS-indused NF-kB activation by the heat shock protein 90 inhibitor, 17-N- allylamino-17-demethoxygeldanamycin, in human lung microvascular endothelial cells / GS Thangjam, C.Dimitropoulou, AD Joshi [et al.] // Am. J. Respir. Cell Mol Biol. – 2014 – Vol.50,N5. – P.942-952.


41. Tomita T. Application of NF-kappa B inhibitor for arthritis / T.Tomito, Y. Kunugiza, K. Nomura [et al.] // Nichon Rinsho Meneki Gakkai Kaishi. – 2009. – Vol.32,N2. – P.71-76.


42. Trask JO. Nuclear factor kappa B (NF-kB) translocation assay development and validation for high content screening / JO.Trask// In: Assay Guidance Manual. Sittampalam S., ed. – Eli Lilly. Co., N.Y.,2012 – P.1-22.


43. Verma IM. Nuclear factor (NF)-kB proteins:therapeutic targets /IM.Verma // Ann. Rheum. Dis. – 2004. – Vol.63,N2. – P.57-61.


44. Wang H. The proteasome inhibitor lactacystin exerts ist therapeutic effects on glioma via apoptosis: an in vitro and in vivo study / H.Wang, S.Zhang, J. Zhong [et al] // Int. Med. Res. – 2013. – Vol.13,N1. – P.1-10.


45. Weber A. Interleukin-1 (IL-1) pathway / A.Weber, P. Wasiliew, M. Kracht // Science Signal. – 2010. – Vol.3,N105. – P.1-6.


46. Xu X.Activation of epidermal growth factor receptor is required for NTHi-induced NF-kB dependent inflammation / X.Xu, RR.Steere, CA.Fedorchuk [et al.] //PLoS ONE. – 2011. – Vol.6,N11. – P.e28216.


47. Yoon JW. ß-Carboline alkaloid suppresse NF-kB transcriptional activity through inhibition of IKK signaling pathway / JW Yoon, IK Kang, KR Lee [et al.] // J. Toxicol.Environ. Health A. – 2005. – Vol.68,N 23-24. – P.2005-2017.


48. Yu M. Protein kinase casein kinase 2 mediates inhibitor-kappaB kinase and aberrant nuclear factor-kappa B activation by serum factor(s) in head and neck squamous carcinoma cells / M.Yu, J. Yeh, C. Van Waes // Cancer Res.- 2006. – Vol.66,N13. – P.6722-6731.


49. Zamanian-Daryoush M. NF-kB activation by double-stranded-DNA-activated protein kinase (PKR) in mediated through NF-kB-inducing kinase and IkB kinase / M.Zamanian-Daryoush, TH Mogensen, JA DiDonato, BRG Williams // Mol. Cell. Biol. -2010 – Vol.20,N4. – P. 1278-1290.


50.Zhang JM. Cytokines, inflammation and pain /JM.Zhang, J.An// Int. Anesthesiol. Clin. – 2007. – Vol.45,N2. – P.27-37.





© Clinical & Experimental Pathology, 2004-2019
When you copy an active link to the material is required
ISSN 2521-1153 (Online)
ISSN 1727-4338 (Print)
tel./fax +38(0372)553754